-
公开(公告)号：US20240360241A1
公开(公告)日：2024-10-31
申请号：US18605139
申请日：2024-03-14
Applicant: Bionomics Inc.
Inventor： Christopher L. Reyes , Peter Chu , Kristen M. Smith , Lioudmila A. Campbell , Farbod Shojaei , John Thomas Norton
IPC: C07K16/30 , A61K31/337 , A61K31/4745 , A61K31/513 , A61K31/519 , A61K31/7068 , A61K39/00 , A61K39/395 , A61K45/06 , C07K16/28
CPC classification number: C07K16/30 , A61K31/337 , A61K31/4745 , A61K31/513 , A61K31/519 , A61K31/7068 , A61K39/39558 , A61K45/06 , C07K16/28 , C07K16/2869 , A61K2039/505 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/77 , C07K2317/92
Abstract: Embodiments include humanized anti-LGR5 antibodies for the treatment of cancer. Some embodiments include antibodies which may bind LGR5 without disrupting LGR5-RSPO1 binding or signaling, and may disrupt LGR5 signaling through Wnt that is independent of RSPO1. Some embodiments include heavy and light chain polypeptide sequences for the binding of LGR5, for example without disrupting LGR5-RSPO binding or signaling.
-
2.发明公开
公开(公告)号：US20240360139A1
公开(公告)日：2024-10-31
申请号：US18601428
申请日：2024-03-11
Applicant: GENOSCO Inc.
Inventor： R. Bruce DIEBOLD , Wongil LEE , William DEVINE , So Young HWANG , Anu GUPTA , Vinay SAGAR , Nicholas NG , Sang-Ae SEUNG , Miyong YONG , Jaekyoo LEE , Jong Sung KOH
IPC: C07D487/04 , A61K31/4155 , A61K31/416 , A61K31/437 , A61K31/519 , C07D405/14 , C07D471/04
CPC classification number: C07D487/04 , A61K31/4155 , A61K31/416 , A61K31/437 , A61K31/519 , C07D405/14 , C07D471/04
Abstract: The present invention relates to novel blood-brain barrier (BBB) penetrable substituted bicyclic derivatives that can selectively inhibit ROCK2 and/or Rho-kinase mediated phosphorylation of myosin light chain phosphates, compositions comprising the derivatives, methods for preparing the derivatives and/or compositions, and methods for using the derivatives and/or compositions.
-
公开(公告)号：US20240360138A1
公开(公告)日：2024-10-31
申请号：US18537700
申请日：2023-12-12
Inventor： Paul B. Fisher , Maurizio Pellecchia , Swadesh K. Das , Timothy P. Kegelman , Bainan Wu , Surya K. De , Jun Wei , Mitchell E. Menezes , Luni Emdad
IPC: C07D487/04 , A61K31/519 , A61K45/06 , A61P35/04 , C07D495/14
CPC classification number: C07D487/04 , A61K31/519 , A61K45/06 , A61P35/04 , C07D495/14
Abstract: Provided herein are, inter alia, compositions that bind to a PDZI domain of MDA-9/Syntenin (syndecan binding protein: SDCBP), thereby inhibiting MDA-9/Syntenin activity, and methods of use of same. The compositions and methods provided herein are useful for treating cancer and preventing cancer metastasis, particularly in cancers that have increased MDA-9/Syntenin expression.
-
公开(公告)号：US20240360134A1
公开(公告)日：2024-10-31
申请号：US18293023
申请日：2022-07-29
Applicant: ACTELION PHARMACEUTICALS LTD
Inventor： David BAUMAN , Zhijie LIU , Tianbao LU
IPC: C07D487/04 , A61K31/519 , A61K31/5365 , A61K31/5377 , A61K31/541 , A61K31/553 , C07D471/04 , C07D519/00
CPC classification number: C07D487/04 , A61K31/519 , A61K31/5365 , A61K31/5377 , A61K31/541 , A61K31/553 , C07D471/04 , C07D519/00
Abstract: The disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprising compounds of formula (I), as well as methods of their use and preparation, are also described.
-
公开(公告)号：US20240358699A1
公开(公告)日：2024-10-31
申请号：US18390000
申请日：2023-12-20
Applicant: CELLTAXIS, LLC
Inventor： Sanjeev Ahuja , Ralph Grosswald , Gregory S. Duncan , Eric B. Springman
IPC: A61K31/4985 , A61K31/47 , A61K31/519 , A61K45/06 , A61P11/00
CPC classification number: A61K31/4985 , A61K31/47 , A61K31/519 , A61P11/00 , A61K45/06 , A61K2121/00
Abstract: Described are methods of reducing pulmonary exacerbations and methods of treating cystic fibrosis, including methods of reducing pulmonary inflammation, comprising administration of an LTA4h inhibitor.
-
公开(公告)号：US12128056B2
公开(公告)日：2024-10-29
申请号：US17365949
申请日：2021-07-01
Applicant: Natals, Inc.
Inventor： Luke Bucci , Katerina Schneider , Mastaneh Sharafi , Nima Alamdari
IPC: A61K31/593 , A23D9/007 , A23L5/00 , A23L33/00 , A23L33/115 , A23L33/12 , A23L33/15 , A23L33/155 , A23L33/16 , A61K9/16 , A61K9/48 , A61K31/122 , A61K31/202 , A61K31/355 , A61K31/519 , A61K31/714 , A61K33/06 , A61K33/22 , A61K33/26 , A61K36/02 , A61K36/31 , B65D25/54 , B65D81/20
CPC classification number: A61K31/593 , A23D9/007 , A23L5/00 , A23L33/115 , A23L33/12 , A23L33/15 , A23L33/155 , A23L33/16 , A23L33/40 , A61K9/1652 , A61K9/1664 , A61K9/1676 , A61K9/4808 , A61K31/122 , A61K31/202 , A61K31/355 , A61K31/519 , A61K31/714 , A61K33/06 , A61K33/22 , A61K33/26 , A61K36/02 , A61K36/31 , B65D25/54 , B65D81/2076 , A23V2002/00 , B65D2203/12 , A23V2002/00 , A23V2200/224 , A23V2200/30 , A23V2250/1572 , A23V2250/1592 , A23V2250/161 , A23V2250/1642 , A23V2250/1882 , A23V2250/202 , A23V2250/5054 , A23V2250/51084 , A23V2250/702 , A23V2250/7056 , A23V2250/706 , A23V2250/71 , A23V2250/712 , A23V2250/714 , A23V2002/00 , A23V2200/224 , A23V2200/30 , A23V2250/1572 , A23V2250/1592 , A23V2250/161 , A23V2250/1882 , A23V2250/202 , A23V2250/5054 , A23V2250/51084 , A23V2250/7056 , A23V2250/706 , A23V2250/71 , A23V2250/712 , A23V2250/714
Abstract: Provided herein are dietary supplement compositions comprising a plurality of beadlets and an oil. Provided herein are also dietary supplement compositions comprising a plurality of mini-tabs and oil. The beadlets or mini-tabs comprise at least one nutrient that is miscible in aqueous solution, and the oil comprises at least one fat-soluble nutrient. The composition may be contained within one or more capsules, and be packaged with a scented insert.
-
公开(公告)号：US12128049B2
公开(公告)日：2024-10-29
申请号：US18305303
申请日：2023-04-21
Applicant: Luye Innomind Pharma Shijiazhuang Co., Ltd.
Inventor： Youxin Li , Chunjie Sha , Fengjuan Zhao , Changbing Tu , Kaoxiang Sun , Wanhui Liu , Lifang Sun , Ying Meng
IPC: A61K31/519 , A61K9/00
CPC classification number: A61K31/519 , A61K9/0019
Abstract: Provided herein are simplified dosing regimens for administering paliperidone palmitate to a patient in need of treatment of schizophrenia or schizoaffective disorders.
-
公开(公告)号：US12128048B2
公开(公告)日：2024-10-29
申请号：US17713472
申请日：2022-04-05
Applicant: Mirati Therapeutics, Inc.
Inventor： Lars Daniel Engstrom , Peter Olson , James Gail Christensen
IPC: A61K31/519 , A61K31/416 , A61K31/502 , A61K31/517 , A61P35/00
CPC classification number: A61K31/519 , A61K31/416 , A61K31/502 , A61K31/517 , A61P35/00 , A61K31/519 , A61K2300/00 , A61K31/517 , A61K2300/00 , A61K31/502 , A61K2300/00
Abstract: This disclosure relates to methods of treating cancer. This disclosure further relates to treating cancer in a subject with compounds that are inhibitors of PRMT5, particularly in combination with KRASG12C inhibitors.
-
公开(公告)号：US20240350504A1
公开(公告)日：2024-10-24
申请号：US18530663
申请日：2023-12-06
Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
Inventor： Eulalia Baselga , Pau Castel , Jose Baselga
IPC: A61K31/5377 , A61K31/427 , A61K31/4375 , A61K31/4439 , A61K31/444 , A61K31/519 , A61P9/00
CPC classification number: A61K31/5377 , A61K31/427 , A61K31/4375 , A61K31/4439 , A61K31/444 , A61K31/519 , A61P9/00
Abstract: The present disclosure relates to methods of treating a vascular malformation in a subject expressing a gain-of-function mutation in a PIK3CA gene comprising administering, to the subject, an effective amount of an agent that inhibits phosphoinositide 3-kinase (“PI3K”).
-
公开(公告)号：US20240350500A1
公开(公告)日：2024-10-24
申请号：US18751006
申请日：2024-06-21
Applicant: CARDIFF ONCOLOGY, INC.
Inventor： Maya Ridinger , Mark Erlander
IPC: A61K31/519 , A61K9/00 , A61K31/4745 , A61K31/513 , A61K39/00 , A61K45/06 , A61P35/04 , C07K16/22
CPC classification number: A61K31/519 , A61K9/0053 , A61K31/4745 , A61K31/513 , A61K45/06 , A61P35/04 , C07K16/22 , A61K2039/505 , A61K2039/545
Abstract: Provided include methods, compositions and kits for treating metastatic cancer in a subject. The method can comprise administrating a treatment comprising inhibiting angiogenesis and a PLK1 inhibitor (for example, onvansertib) to the subject that has not received prior anti-angiogenic treatment, in a manner sufficient to reduce or inhibit progression of the metastatic cancer.
